Frequently Asked Questions

What is the primary objective of an IND-enabling toxicology study for an AAV therapy?

The study is designed to define the No Observed Adverse Effect Level (NOAEL), characterize the biological response across exposure levels, and identify potential target organ toxicities. This data is used to establish a safe starting level for first-in-human clinical trials.

Why are predictive biological systems often required for AAV toxicology?

The immunological and physiological similarity of certain species to humans provides the most predictive data on vector biodistribution, transgene expression, and potential immune responses. These complex interactions are not always sufficiently captured in rodent systems.

How does GLP compliance impact the study design?

GLP conditions mandate rigorous documentation, quality assurance oversight, and validated, standard procedures for every phase of the program. This framework covers test article formulation, in-life conduct, bioanalysis, and final reporting, ensuring the integrity and reproducibility of the safety data for regulatory submission.

A standardized template for preclinical toxicology does not exist for AAV-based Advanced Therapeutics and Complex Biologics. Each program requires a science-based, data-driven strategy tailored to the specific vector, transgene, and target indication. Applying proven intelligence in IND-enabling toxicology is how our teams accelerate these programs. This team’s track record, which includes a 100% successful IND rate since 2019, now forms the operational foundation of Franklin Biolabs following its 2024 launch.

The transition from a controlled in-vitro environment to a complex biological system introduces significant variables. This is particularly true for AAV vectors like AAV8 and AAV9, where factors like pre-existing immunity and capsid-specific tropism can influence the safety profile.

Preclinical safety evaluations must accurately model both the intended clinical delivery route and the specific vector characteristics to produce relevant data. The continuous development of new recombinant AAV serotypes offers an expanding toolkit for precise tissue targeting, but each vector possesses a distinct biodistribution profile that dictates its safety and efficacy (PMID: 15975006). A mismatch between the preclinical design—encompassing both vector and administration—and the clinical plan can generate data that fails to minimize patient risk.

Our scientific approach is built on a collaborative, peer-to-peer framework. We design IND-enabling toxicology programs under GLP conditions with a focus on regulatory expectations and scientific validity.

Design considerations include:

• Species Selection: Justification of the relevant biological system, often requiring a species with an immune system that closely mirrors the human response.
• Exposure Level Selection: Execution of non-GLP studies to identify limiting toxicities and inform the level selection for the pivotal GLP study.
• Assay Development: Phase-appropriate development and validation of all immunogenicity and bioanalytical assays in compliance with GCLP guidelines.
• Study Conduct: Long-term observation periods to monitor for delayed toxicities, supported by enhanced housing conditions and cognitive enrichment programs during the in-life phase.

Executing these complex programs correctly is a scientific and ethical necessity. “We have to do research in living systems, so let’s do it well. Let’s do it right the first time, right? The most important thing is to do it right the first time so you’re not using any more biological resources than you’re absolutely required to,” states Dr. Naageshwaran. This philosophy directly supports the goal of getting candidates to IND in 18-24 months by generating definitive data that withstands regulatory scrutiny.

Learn more about our full suite of Preclinical | Translational Services.